Adagene receives USD 2 million Exelixis milestone payment for SAFEbody ADC program
ADAG•Milestone payment from Exelixis
Adagene reported a USD 2 million milestone payment from Exelixis tied to a preclinical milestone for SAFEbody ADC candidate XB404.
Additional collaboration payment
Exelixis also triggered an additional payment by selecting candidates for another SAFEbody antibody-drug conjugate program.
Further potential under the collaboration
Adagene remains eligible for further development and commercialization milestones, as well as royalties on net sales, under the collaboration.
